SCHEMBL1102283

SCHEMBL1102283

COC(=O)Nc1ccc2c(c1)C(C)(C)c1c-2[nH]c2c(F)c(-c3ccc(N4CCCCC4)cc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 4/20 0.48
RAB9A P51151 9/20 0.38
SMN1; SMN2 Q16637 8/20 0.38
NPC1 O15118 7/20 0.38
TP53 P04637 5/20 0.38
ALOX15 P16050 2/20 0.38
HTT P42858 2/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 3/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 1/20 0.38
HPGD P15428 1/20 0.37
MAPT P10636 7/20 0.37
TSHR P16473 1/20 0.37
GFER P55789 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102282 0.91 MPL (0.49) MPLRAB9ASMN1; SMN2NPC1TP53
SCHEMBL1091882 0.84 MPL (0.66) MPLRAB9ASMN1; SMN2NPC1TP53
SCHEMBL1102085 0.83 MPL (0.57) MPLRAB9ASMN1; SMN2NPC1TP53
SCHEMBL1102236 0.81 MPL (0.49) MPLRAB9ASMN1; SMN2NPC1TP53
SCHEMBL1102077 0.74 MPL (0.69) MPLRAB9ASMN1; SMN2NPC1TP53
SCHEMBL1102143 0.72 MPL (0.57) MPLRAB9ASMN1; SMN2NPC1TP53
SCHEMBL1091702 0.72 GAA (0.39) MPLSMN1; SMN2MAPK1KMT2ALMNA
SCHEMBL1102197 0.70 MPL (0.48) MPLRAB9ASMN1; SMN2NPC1TP53
SCHEMBL1102116 0.68 MPL (0.68) MPLRAB9ANPC1TP53MAPK1
SCHEMBL1102218 0.68 MPL (0.51) MPLSMN1; SMN2MAPK1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO MPL 1/4885RAB9A 1352/4885SMN1; SMN2 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.